ニュース

COVID-19: Prime Minister of India's Meets Pharma leaders

On October 23, 2021, Prime Minister Narendra Modi met Indian COVID-19 vaccine manufacturers, including Dr. Reddy's. During the meeting, Modi discussed various issues, including furthering the vaccine research. Modi said – "All over the world now, countries are going to invest in vaccine production, and India needs to stay ahead. He discussed how to do that together with industry and government."

Satish Reddy, chairman, Dr. Reddy's, and Deepak Sapra, CEO – API & Services, represented the event. This is a landmark moment for Dr. Reddy's in the combat against the COVID-19 pandemic.

Dr. Reddy's is the front-runner in catering to the formulators around the world with its vast COVID-19 API Portfolio. From prevention to treatment, our portfolio of COVID-19 products addresses the most critical need of the patients.

Our Portfolio of Anti-Covid APIs Include:

Remdesivir:

We have partnered with US company Gilead Sciences, innovators of Remdesivir, to make the product available for COVID-19 patients globally. Remdesivir is an injectable antiviral drug that stops the multiplication of the infection-causing virus, thereby decreasing the body's viral load.

2-DG:

2-DG or 2-Deoxy-D-Glucose is an antiviral and anti-inflammatory drug co-developed and manufactured by Dr. Reddy's Laboratories. Discovered by the Institute of Nuclear Medicine & Allied Sciences of India's Defence Research and Development Organisation (DRDO), 2-DG has been co-developed by Dr. Reddy's Laboratories as an adjunct therapy for Covid-19.

Molnupiravir:

We have collaborated with American company Merck & Co, innovators of Molnupiravir, to make the product accessible to COVID-19 patients worldwide. Molnupiravir is an investigational oral antiviral drug that inhibits the multiplication of the infection-causing virus, thereby decreasing the viral load in the body. It is currently undergoing Phase 3 clinical studies globally for treating mild to moderate COVID-19.

Baricitinib:

Our partnership with the US-based Eli Lilly and Company, innovators of Baricitinib, will enable us to bring the product to India. Baricitinib is an oral drug that reduces the body's unwanted inflammatory response to COVID-19. It also prevents the entry of the virus, causing the disease into cells.

Favipiravir:

Our partnership with Japan's Fujifilm Toyama Chemical, innovators of Favipiravir, will enable us to make the product accessible to COVID-19 patients around the world. Favipiravir is an oral antiviral drug that works by inhibiting the multiplication of the infection-causing virus, thus decreasing the viral load in the body.

To know more about our COVID-19 API Portfolio, please connect directly by writing to api@drreddys.com or via our service platform XCEED, which connects you with our different team members and ensures the fastest response times.